IFNAR2
ENSG00000159110
Target class
Membrane receptor
Chromosome
21
Approved drugs
10
Clinical candidates (approved and in development)
11
- Approved drugs
- 10
- Clinical candidates (approved and in development)
- 11
- Chemical probe available
- No
- Target name
- IFNAR2
- Gene name
- Interferon alpha and beta receptor subunit 2
- Gene symbol
- IFNAR2
- Previous gene symbols
- IFNABR
- Protein name
- Interferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/beta receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2)
- Gene biotype
- Protein coding
- Gene family
- Interferon receptors
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 66.66
- Tissue specificity (Gini)
- 0.359
- Tissue specificity (tau)
- 0.817
- KEGG gene identifiers
- hsa:3455
- Protein interaction confidence
- 0.863857
- Protein interaction partners
- 56
- End position
- 33265675
- Start position
- 33205282
- Chromosome
- 21
- Strand
- Forward
- [Isoform 1]: Cell membrane
- Single-pass type I membrane protein .
- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
- Single-pass type I membrane protein .
- SUBCELLULAR LOCATION: [Isoform 3]: Secreted .
- PubMed 7665574
- PubMed 7759950
- PubMed 8181059
- Tissue specificity (tau)
- 0.816693
- Expression inequality (Gini)
- 0.358942
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 66.66
- Spleen
- 40.37
- Whole Blood
- 30.44
- Nerve - Tibial
- 29.93
- Lung
- 28.49
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes66.66
- Spleen40.37
- Whole Blood30.44
- Nerve - Tibial29.93
- Lung28.49
- Adipose - Subcutaneous20.8
- Adipose - Visceral (Omentum)19.75
- Artery - Aorta19.22
- Cervix - Endocervix19.21
- Artery - Coronary19.1
- Breast - Mammary Tissue18.45
- Small Intestine - Terminal Ileum17.4
- Uterus16.73
- Bladder16.69
- Fallopian Tube15.78
- Cells - Cultured fibroblasts14.6
- Thyroid14.46
- Cervix - Ectocervix14.16
- Ovary13.57
- Minor Salivary Gland13.45
- Prostate12.51
- Colon - Sigmoid12.48
- Esophagus - Muscularis12.07
- Pituitary11.81
- Esophagus - Gastroesophageal Junction11.78
And 29 more, listed on the interactive page.
- GO:0007166
- GO:0007259
- GO:0009615
- GO:0035455
- GO:0035456
- GO:0035458
- GO:0051607
- GO:0060337
- GO:0005576
- GO:0005886
- GO:0004905
- GO:0005515
- GO:0008269
- GO:0019901
- GO:0019955
Related records
Trials (2,033)
- 'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT
- (Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI
- 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)
- 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
- 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
- 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
- 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
- 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8
- 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
- 48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection
- 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)
- 5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
- A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
- A Clinical Study of MIL93 in Solid Tumors.
- A Clinical Study of MIL95 in Advanced Malignancies.
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
- A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
Drugs (11)
- Albinterferon alfa-2B Interferon alpha/beta receptor agonist
- Interferon alfa-2A Interferon alpha/beta receptor agonist
- Interferon alfa-2B Interferon alpha/beta receptor agonist
- Interferon alfa-N3 Interferon alpha/beta receptor agonist
- Interferon alfacon-1 Interferon alpha/beta receptor agonist
- Interferon beta-1A Interferon alpha/beta receptor agonist
- Interferon beta-1B Interferon alpha/beta receptor agonist
- Peginterferon alfa-2A Interferon alpha/beta receptor agonist
- Peginterferon alfa-2B Interferon alpha/beta receptor agonist
- Peginterferon beta-1A Interferon alpha/beta receptor agonist
- Ropeginterferon alfa-2B Interferon alpha/beta receptor positive modulator